SCHEMBL2709980

SCHEMBL2709980

Fc1cc(F)c(F)c(-c2c3ccccc3c(-c3ccccc3)c3ccccc23)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 4/20 0.40
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP2C9 P11712 1/20 0.39
ESR1 P03372 6/20 0.39
ESR2 Q92731 4/20 0.39
KDM4E B2RXH2 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MAPT P10636 2/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HTT P42858 2/20 0.35
HPGD P15428 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.33
MAP2 P11137 1/20 0.33
GPR84 Q9NQS5 1/20 0.33
EGFR P00533 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2710628 0.94 ACHE (0.37) ACHECYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL2713008 0.89 MAOB (0.39) ACHECYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL2709935 0.89 HPRT1 (0.37) ACHECYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL2713398 0.88 KDM4E (0.32) ACHECYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL2711448 0.86 CYP1A2 (0.50) ACHECYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL2711234 0.85 ACHE (0.41) ACHECYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL2725664 0.85 CYP1A2 (0.42) ACHECYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL2726679 0.85 CYP1A2 (0.39) ACHECYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL2710236 0.85 ACHE (0.44) ACHECYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL2727495 0.85 NPSR1 (0.39) CYP1A2CYP3A4CYP2C19KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2445987-B1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS CYALUME TECH INC (US) 2018-05-02 EP disclosed
US-8257620-B2 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. (US) 2012-09-04 US disclosed
CN-102482573-A Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES INC 2012-05-30 CN disclosed
EP-2445987-A1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS Cyalume Technologies, Inc (US) 2012-05-02 EP disclosed
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. 2010-12-30 US disclosed
WO-2010151654-A1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS CYALUME TECHNOLOGIES, INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYP2F1, FLAD1, AFF1 ACHE 187/4885CYP1A2 22/4885CYP3A4 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.